Krystal Biotech, Inc. — Form 10-Q
Filed November 2, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Krish S. Krishnan (CEO) and Kathryn A. Romano (Chief Accounting Officer) certified the Q3 2026 Form 10-Q filed November 2, 2026. Both officers attest that the filing contains no untrue material facts, that financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls over financial reporting are designed and operating effectively. No material weaknesses, significant deficiencies, or material fraud disclosures were identified.
Why this rating
Routine SOX 302/906 officer certifications with no disclosed control deficiencies, material weaknesses, or restatements. Standard quarterly compliance filing.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.